18487429. SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER simplified abstract (Board of Regents, The University of Texas System)
Contents
- 1 SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER
Organization Name
Board of Regents, The University of Texas System
Inventor(s)
Mariano A. Garcia-blanco of Galveston TX (US)
Gaddiel Galarza-munoz of Galveston TX (US)
Shelton S. Bradrick of Galveston TX (US)
SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER - A simplified explanation of the abstract
This abstract first appeared for US patent application 18487429 titled 'SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER
Simplified Explanation
The present invention involves using an oligonucleotide to treat autoimmune disorders or cancer by targeting the Interleukin-7 receptor pre-mRNA to modulate splicing and expression of the soluble isoform of IL7R.
- Oligonucleotide specifically binds to IL7R pre-mRNA to influence splicing of exon 6.
- SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs, leading to changes in sIL7R expression.
Potential Applications
The technology can be applied in the treatment of autoimmune disorders and cancer by targeting the IL7R pre-mRNA to modulate gene expression.
Problems Solved
This technology addresses the need for more targeted and effective treatments for autoimmune disorders and cancer by specifically modulating gene expression.
Benefits
- Targeted treatment for autoimmune disorders and cancer - Modulation of gene expression for therapeutic purposes
Potential Commercial Applications
The technology could be utilized in the development of novel therapies for autoimmune disorders and cancer, potentially leading to new treatment options for patients.
Possible Prior Art
Prior research has shown the potential of antisense oligonucleotides in modulating gene expression, but the specific targeting of IL7R pre-mRNA for the treatment of autoimmune disorders and cancer appears to be a novel application.
Unanswered Questions
== How does the oligonucleotide specifically bind to the complementary sequence of IL7R pre-mRNA? The mechanism by which the oligonucleotide interacts with the IL7R pre-mRNA to influence splicing of exon 6 is not fully explained in the abstract.
== What are the potential side effects or limitations of using this oligonucleotide-based treatment? The abstract does not provide information on any potential drawbacks or limitations of using this technology for treating autoimmune disorders or cancer.
Original Abstract Submitted
The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
